138 related articles for article (PubMed ID: 6512001)
1. Possible interference by the reduced haloperidol metabolite with the radioimmunoassay and radioreceptor assay of blood haloperidol.
Korpi ER; Ko GN; Phelps BH; Wyatt RJ
J Clin Psychopharmacol; 1984 Dec; 4(6):332-5. PubMed ID: 6512001
[TBL] [Abstract][Full Text] [Related]
2. Determination of haloperidol and hydroxy haloperidol in human plasma by high performance liquid chromatography.
Pommery J; Foulon O; Morineau G; Lhermitte M; Levron JC; Erb F
Ann Biol Clin (Paris); 1990; 48(7):455-8. PubMed ID: 2278409
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of delta 4-reduced metabolite of norethindrone in human plasma by HPLC-RIA.
Ho-Ngoc A; Loo JC; Stanczyk FZ; Menzies JA; Jordan N; Watanabe H
Res Commun Chem Pathol Pharmacol; 1984 May; 44(2):307-13. PubMed ID: 6739957
[TBL] [Abstract][Full Text] [Related]
4. Neuroleptic radioreceptor activity and clinical outcome in schizophrenia.
Contreras S; Alexander H; Faber R; Bowden C
J Clin Psychopharmacol; 1987 Apr; 7(2):95-8. PubMed ID: 3584527
[TBL] [Abstract][Full Text] [Related]
5. Serum haloperidol and neuroleptic receptor levels in chronic psychosis.
Cannon DJ; McMillan DE; Newton JE; Fody EP; Metzer WS; Claybrook M; Couch L; Paige SR
Ann Clin Lab Sci; 1988; 18(5):378-83. PubMed ID: 3178137
[TBL] [Abstract][Full Text] [Related]
6. Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility.
Santos JL; Ramos JA; Prieto P; Almoguera I; Vazquez C; Rubio ME; Cabranes JA
Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(6):917-25. PubMed ID: 2813809
[TBL] [Abstract][Full Text] [Related]
7. [HPLC, RIA, FPIA. Evaluation of 3 methods for the assay of vancomycin].
Jehl F; Monteil H; Gallion C; Thierry RC
Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):511-6. PubMed ID: 3911145
[TBL] [Abstract][Full Text] [Related]
8. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
Ereshefsky L; Davis CM; Harrington CA; Jann MW; Browning JL; Saklad SR; Burch NR
J Clin Psychopharmacol; 1984 Jun; 4(3):138-42. PubMed ID: 6736273
[TBL] [Abstract][Full Text] [Related]
9. Quantification of reduced haloperidol and haloperidol by radioimmunoassay.
Browning JL; Harrington CA; Davis CM
J Immunoassay; 1985; 6(1-2):45-66. PubMed ID: 4019788
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone assessment by radioreceptor and radioimmunoassay. Radioreceptor assay and radioimmunoassay comparisons.
LaFranchi S; Hanna CE; Jelen B
Am J Dis Child; 1984 Jan; 138(1):23-7. PubMed ID: 6537873
[TBL] [Abstract][Full Text] [Related]
11. Neuroleptic monitoring: relation between antipsychotic efficiency and radioreceptor assay of serum haloperidol.
Odou P; Vaiva G; Luyckx M; Brunet C; Dine T; Gressier B; Cazin M; Cazin JC
Eur J Clin Pharmacol; 1996; 50(5):357-63. PubMed ID: 8839656
[TBL] [Abstract][Full Text] [Related]
12. Semiquantitative use of Biocept-G radioreceptorassay.
Hussa RO; Mattingly RF
Obstet Gynecol; 1979 Aug; 54(2):199-204. PubMed ID: 460754
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection.
Korpi ER; Phelps BH; Granger H; Chang WH; Linnoila M; Meek JL; Wyatt RJ
Clin Chem; 1983 Apr; 29(4):624-8. PubMed ID: 6831688
[TBL] [Abstract][Full Text] [Related]
14. Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol.
Eyles DW; Whiteford HA; Stedman TJ; Pond SM
Psychopharmacology (Berl); 1992; 106(2):268-74. PubMed ID: 1549652
[TBL] [Abstract][Full Text] [Related]
15. Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas-liquid chromatography and radioreceptor drug level assays.
Smith RC; Baumgartner R; Burd A; Ravichandran GK; Mauldin M
Psychopharmacol Bull; 1985; 21(1):52-8. PubMed ID: 3983338
[No Abstract] [Full Text] [Related]
16. Serum haloperidol concentrations and clinical response in acute psychosis.
Miller DD; Hershey LA; Duffy JP; Abernethy DR; Greenblatt DJ
J Clin Psychopharmacol; 1984 Dec; 4(6):305-10. PubMed ID: 6511996
[TBL] [Abstract][Full Text] [Related]
17. Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction.
Someya T; Shibasaki M; Noguchi T; Takahashi S; Inaba T
J Clin Psychopharmacol; 1992 Jun; 12(3):169-74. PubMed ID: 1629382
[TBL] [Abstract][Full Text] [Related]
18. Analysis of buprenorphine in urine specimens.
Debrabandere L; Van Boven M; Daenens P
J Forensic Sci; 1992 Jan; 37(1):82-9. PubMed ID: 1545216
[TBL] [Abstract][Full Text] [Related]
19. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance.
Jann MW; Saklad SR; Ereshefsky L; Richards AL; Harrington CA; Davis CM
Psychopharmacology (Berl); 1986; 90(4):468-70. PubMed ID: 3101102
[TBL] [Abstract][Full Text] [Related]
20. Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.
Rimón R; Averbuch I; Rozick P; Fijman-Danilovich L; Kara T; Dasberg H; Ebstein RP; Belmaker RH
Psychopharmacology (Berl); 1981; 73(2):197-9. PubMed ID: 6785816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
